To boost Singapore’s biopharmaceutical sector, Australia-based Lendlease is commencing construction of a large-scale, greenfield vaccine facility in late 2021.

This new facility will leverage Lendlease’s digital capabilities and best practices in construction focused on maximizing quality, speed, precision, and safety, as well as its deep experience in the sector. Lendlease has built the majority of Singapore’s major pharmaceutical facilities and more than 90 percent of the biotechnology facilities in the island state’s Tuas Biomedical Park, a 280-hectare specialized industrial park that is master-planned and developed by JTC, since the late 1990s. 

Other than the vaccine facility, Lendlease has also been recently appointed to take on additional projects for current clients in Singapore. These works include expansion to existing facilities to enhance their capacities.

Lendlease’s global expertise facilitates the construction of research laboratories, manufacturing facilities, cold rooms, and warehousing while achieving safety and sustainability outcomes.